Abstract 45: BTM-3528 potently induces G1/G0 cell cycle arrest and is efficacious in preclinical models of diffuse large B-cell lymphoma
Bibliographic record
Abstract
Abstract Aberrant regulation of cell cycle control, integration of signals from oncogenic signaling pathways, and cancer cell metabolism play a key role in the pathogenesis of multiple hematologic malignancies and solid tumors. BTM-3528 is an orally available compound that causes concentration-dependent cell cycle arrest in the G0/G1 phase of the cell cycle, rapidly decreases cellular glutathione levels, induces expression of p21, and decreases expression of Cyclin D 1/3. BTM-3528 has no significant biochemical activity against a panel of known drug targets such as kinases (including cyclin-dependent kinases), G-protein coupled receptors, ion channels, and histone deacetylases. For the described study, the activity of BTM-3528 was evaluated in in vitro and in vivo models of diffuse large B-cell lymphoma (DLBCL). Profiling of BTM-3528 across a panel of hematologic and solid tumor cancer cell lines demonstrated potent antiproliferative activity against a select set of cancer cell types without effect on normal human cells. These included multiple DLBCL cell lines notably of germinal center B-cell (GCB) subtype. The majority of the DLBCL cell lines tested were characterized by Myc and Bcl-2 gene rearrangements or amplifications. Cell proliferation was 100% inhibited with IC50s ranging from 0.14 to 0.52 μM in these DLBCL cell lines. BTM-3528 induced apoptosis with caspase 3/7 activation and decreased Mcl1 protein expression at concentrations associated with cell growth inhibition. In vivo pharmacokinetic studies showed that BTM-3528 has excellent oral bioavailability with a murine t ½ of 6 hours. BTM-3528 was tested in a human subcutaneous DLBCL xenograft model (BJAB). Post tumor implantation, animals with tumors ≥ 250 mm3 were treated with BTM-3528 at the maximum tolerated dose of 75 mg/kg once daily orally for 14 days. Significant antitumor activity was observed after 3 days of treatment followed by sustained tumor regressions. Furthermore, following discontinuation of BTM-3528 after 14 days of treatment, sustained complete tumor regressions were maintained in 50% of the treated animals. Preliminary toxicology evaluation of BTM-3528 showed no adverse effect on hematopoiesis or hepatic function. Conclusion: BTM-3528 is a novel orally bioavailable compound with a unique mechanism of action based on G1/G0 cell cycle arrest and modulation of cancer cell metabolism. It shows significant activity and a favorable toxicity profile in in vitro and in vivo models of DLBCL. These results support the clinical development potential of BTM-3528 for the treatment of DLBCL. Citation Format: Matthew Kostura, Jedd Levine, Vibha Oza, Alan Cooper, Meztli Arguello, Peter W. White, Stephane Ciblat, Anthony Regina, Edith Bellavance, Martine Brault, Arshad Siddiqui, Michael Luther. BTM-3528 potently induces G1/G0 cell cycle arrest and is efficacious in preclinical models of diffuse large B-cell lymphoma [abstract]. In: Proceedings of the Second AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; May 6-9, 2017; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(24_Suppl):Abstract nr 45.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".